Pompe disease registry for people with confirmed diagnosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This trial is a registry, meaning it collects health information from people with confirmed Pompe disease. It may help researchers better understand the disease and improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of Pompe disease
- Your diagnosis should be proven by specific test results (enzyme test and/or gene changes)
- You must be able to sign the informed consent forms
- You do not need to meet any other study-specific limits (no listed exclusions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is a registry study that collects information over time from people with Pompe disease. It helps doctors and researchers better understand the condition and how it affects daily life, without testing any new treatments.
This study follows people with Pompe disease over time and checks their “CRIM status,” which is a lab result about a key protein. It may help researchers better understand the disease and how it progresses for different patient groups.
This study looks at how Pompe disease affects the brain and nervous system. You may be able to join if you have a confirmed diagnosis of infantile or late-onset Pompe disease and agree to participate.
This trial tests whether a higher dose of the enzyme medicine used for Pompe disease is safe and helpful. You may qualify if you already have Pompe disease and are currently receiving regular enzyme replacement therapy.
This study follows people with Pompe disease over a long period to learn how they do over time, especially those receiving enzyme replacement therapy. Your results could help doctors better understand expected outcomes and refine care.
This trial tests if getting enzyme replacement therapy every 4 weeks instead of every 2 weeks is safe and effective for stable adults with late-onset Pompe disease. It may reduce the burden of frequent infusions.
Hear when a new Glycogen Storage Disease Type II trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.